DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci

Objectives: To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. Methods: A multicentre...

Descripción completa

Detalles Bibliográficos
Autores: Hidalgo-Tenorio, Carmen, Vinuesa, David, Plata Ciezar, Antonio, Martín Dávila, Pilar, Iftimie, Simona Mihaela, Sequera, Sergio, Loeches, Belén, Lopez-Cortés, Luis Eduardo, Fariñas, Mari Carmen, Fernández-Roldan, Concepción, Javier-Martinez, Rosario, Muñoz-Millán, Patricia, Arenas-Miras, María Del Mar, Martínez-Marcos, Francisco Javier, Miró, José María, Herrero, Carmen, Bereciartua, Elena, de Jesús, Samantha E., Pasquau, Juan
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/46599
Acceso en línea:http://hdl.handle.net/10230/46599
http://dx.doi.org/10.1186/s12941-019-0329-6
Access Level:acceso abierto
Palabra clave:Bloodstream infection
Dalbavancin
Endocarditis
id ES_d9e81cb79cd036aeba09a3f29cbb88c0
oai_identifier_str oai:recercat.cat:10230/46599
network_acronym_str ES
network_name_str España
repository_id_str
spelling DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocciHidalgo-Tenorio, CarmenVinuesa, DavidPlata Ciezar, AntonioMartín Dávila, PilarIftimie, Simona MihaelaSequera, SergioLoeches, BelénLopez-Cortés, Luis EduardoFariñas, Mari CarmenFernández-Roldan, ConcepciónJavier-Martinez, RosarioMuñoz-Millán, PatriciaArenas-Miras, María Del MarMartínez-Marcos, Francisco JavierMiró, José MaríaHerrero, CarmenBereciartua, Elenade Jesús, Samantha E.Pasquau, JuanBloodstream infectionDalbavancinEndocarditisObjectives: To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. Methods: A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. Results: Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20€) and 557 days for IE (283,187.45€). Conclusions: DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug.BioMed Central202120212019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/46599http://dx.doi.org/10.1186/s12941-019-0329-6reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésCopyright © The Author(s) 2019. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/465992026-05-29T05:05:01Z
dc.title.none.fl_str_mv DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
title DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
spellingShingle DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
Hidalgo-Tenorio, Carmen
Bloodstream infection
Dalbavancin
Endocarditis
title_short DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
title_full DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
title_fullStr DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
title_full_unstemmed DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
title_sort DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
dc.creator.none.fl_str_mv Hidalgo-Tenorio, Carmen
Vinuesa, David
Plata Ciezar, Antonio
Martín Dávila, Pilar
Iftimie, Simona Mihaela
Sequera, Sergio
Loeches, Belén
Lopez-Cortés, Luis Eduardo
Fariñas, Mari Carmen
Fernández-Roldan, Concepción
Javier-Martinez, Rosario
Muñoz-Millán, Patricia
Arenas-Miras, María Del Mar
Martínez-Marcos, Francisco Javier
Miró, José María
Herrero, Carmen
Bereciartua, Elena
de Jesús, Samantha E.
Pasquau, Juan
author Hidalgo-Tenorio, Carmen
author_facet Hidalgo-Tenorio, Carmen
Vinuesa, David
Plata Ciezar, Antonio
Martín Dávila, Pilar
Iftimie, Simona Mihaela
Sequera, Sergio
Loeches, Belén
Lopez-Cortés, Luis Eduardo
Fariñas, Mari Carmen
Fernández-Roldan, Concepción
Javier-Martinez, Rosario
Muñoz-Millán, Patricia
Arenas-Miras, María Del Mar
Martínez-Marcos, Francisco Javier
Miró, José María
Herrero, Carmen
Bereciartua, Elena
de Jesús, Samantha E.
Pasquau, Juan
author_role author
author2 Vinuesa, David
Plata Ciezar, Antonio
Martín Dávila, Pilar
Iftimie, Simona Mihaela
Sequera, Sergio
Loeches, Belén
Lopez-Cortés, Luis Eduardo
Fariñas, Mari Carmen
Fernández-Roldan, Concepción
Javier-Martinez, Rosario
Muñoz-Millán, Patricia
Arenas-Miras, María Del Mar
Martínez-Marcos, Francisco Javier
Miró, José María
Herrero, Carmen
Bereciartua, Elena
de Jesús, Samantha E.
Pasquau, Juan
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Bloodstream infection
Dalbavancin
Endocarditis
topic Bloodstream infection
Dalbavancin
Endocarditis
description Objectives: To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. Methods: A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. Results: Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20€) and 557 days for IE (283,187.45€). Conclusions: DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug.
publishDate 2019
dc.date.none.fl_str_mv 2019
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/46599
http://dx.doi.org/10.1186/s12941-019-0329-6
url http://hdl.handle.net/10230/46599
http://dx.doi.org/10.1186/s12941-019-0329-6
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421478675480577
score 15,812429

Similares en LA Referencia